针对脑癌！威尚生物ATM抗病毒抑制剂在美国获批临床

, the three campuses of Mayo Clinic.

"We are very pleased that the FDA has approved the application of IND, which is a significant development milestone in advancing our Portfolio," said Wei Zhong, Ph.D., CEO and Founder of Wayshine Biopharm. " The high potency, high selectivity, good brain penetration with good PK, non-Aldehyde Oxidase substrate, good safety window of WSD0628 significantly prolonged overall survival in intracranial pdx models including but not limit to GBM, DIPG and cancers with brain mets when combo with radiation. The discovery of WSD0628 truly reflects our innovation and commitments and the clinical potential has been recognized and endorsed by the FDA, for this substantial unmet medical need. Really appreciate collaborator Mayo Clinic for strong support and FDA's help during the IND review, and look forward to the excellent performance of WSD0628 in clinical practice “.

ABOUT WAYSHINE BIOPHARM

Wayshine Biopharm is a global based science-driven innovative organization, focusing primarily on discovery and development of CNS penetrable medicines, for the treatment of brain cancer and cancers with CNS metastasis. The mission of the company is to develop precision medicines to address unmet medical needs of brain cancers. The business model is to use functional genomics to identify pathways and biological targets that could be exploited in the field of medicines, and then to screen designed proprietary compounds with the support from local and international Contract Research Organizations (CROs). Leading program, namely WSD0922, a first-in-class BBB penetrable EGFR/EGFRvIII inhibitor for brain cancers, has received IND approval and orphan drug designation from FDA and phase I/IIA clinical trial is conducted at Mayo Clinic with FDA ODD R01 grant support. WSD0628，a first-in-class BBB penetrable ATM inhibitor as radiosensitizer in combination with radiation therapy for brain cancers, has received FDA IND approval and phase I/IIA clinical trial is conducted at Mayo Clinic with NCI U19 grant support. Strategic pipelines, as example WSD1227 also for brain cancer as monotherapy or combination therapy, are under FDA IND enabling studies. For more information, please visit:

。

肠炎怎么治疗最好最有效
吃什么药可以治疗关节僵硬
人体增强免疫力吃什么
再林阿莫西林颗粒能消炎吗
艾拉莫德片对类风湿关节晨僵管用吗